Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
46.82 MXN
8.90 B MXN
59.20 B MXN
189.25 M
About BioMarin Pharmaceutical Inc.
Sector
Industry
CEO
Alexander Hardy
Website
Headquarters
San Rafael
Founded
1997
FIGI
BBG00PG3KTG7
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
BIOMARIN PHARM STOCK PRICE REJECTED AT SUPPORT LEVEL!BMRN declining stock price got rejected at support level at 86, will this cause the stock to rise in coming days?
N.B!
- BMRN price might not follow the drawn lines . Actual price movements may likely differ from the forecast.
- Let emotions and sentiments work for you
- ALWAYS Use Proper Risk Man
Low risk High Reward BMRN?NASDAQ:BMRN finds itself at a point of fight or flight, cornered and being pinned below all-time highs and just above the 0.5 retracement level. A lot can be said about this company: battles with the FDA following the Martin Shkreli controversy, having product approval delayed, and dealing with the
Rectangle Top/Bottom FishingPossibly a bottom formed, time will tell.
3 year high is 131.95 and 3 year low is 62.88. ATH is 151.75 but price gapped down dramatically from this level in the past.
The top appears to have been in a rectangle that broke to the downside. The bottom trendline of the rectangle is now resistance.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027Yield to maturity
5.51%
Maturity date
May 15, 2027
See all BMRN bonds
Curated watchlists where BMRN is featured.
Related stocks
Frequently Asked Questions
The current price of BMRN is 1,480.00 MXN — it has increased by 5.72% in the past 24 hours. Watch BIOMARIN PHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange BIOMARIN PHARMACEUTICAL stocks are traded under the ticker BMRN.
We've gathered analysts' opinions on BIOMARIN PHARMACEUTICAL future price: according to them, BMRN price has a max estimate of 2,562.54 MXN and a min estimate of 1,321.94 MXN. Watch BMRN chart and read a more detailed BIOMARIN PHARMACEUTICAL stock forecast: see what analysts think of BIOMARIN PHARMACEUTICAL and suggest that you do with its stocks.
BMRN reached its all-time high on Jul 9, 2020 with the price of 2,880.00 MXN, and its all-time low was 1,287.65 MXN and was reached on Oct 7, 2019. View more price dynamics on BMRN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BMRN stock is 5.41% volatile and has beta coefficient of 0.40. Track BIOMARIN PHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMACEUTICAL there?
Today BIOMARIN PHARMACEUTICAL has the market capitalization of 236.03 B, it has decreased by −1.30% over the last week.
Yes, you can track BIOMARIN PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMACEUTICAL is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
BMRN earnings for the last quarter are 13.34 MXN per share, whereas the estimation was 11.13 MXN resulting in a 19.84% surprise. The estimated earnings for the next quarter are 13.98 MXN per share. See more details about BIOMARIN PHARMACEUTICAL earnings.
BIOMARIN PHARMACEUTICAL revenue for the last quarter amounts to 15.57 B MXN, despite the estimated figure of 14.85 B MXN. In the next quarter, revenue is expected to reach 15.13 B MXN.
BMRN net income for the last quarter is 2.60 B MXN, while the quarter before that showed 2.09 B MXN of net income which accounts for 24.63% change. Track more BIOMARIN PHARMACEUTICAL financial stats to get the full picture.
No, BMRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 25, 2025, the company has 3.04 K employees. See our rating of the largest employees — is BIOMARIN PHARMACEUTICAL on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMACEUTICAL EBITDA is 11.92 B MXN, and current EBITDA margin is 22.06%. See more stats in BIOMARIN PHARMACEUTICAL financial statements.
Like other stocks, BMRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMACEUTICAL technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMACEUTICAL stock shows the sell signal. See more of BIOMARIN PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.